S&P 500   4,543.60 (-0.15%)
DOW   35,683.43 (+0.71%)
QQQ   386.91 (-0.74%)
AAPL   188.57 (-0.42%)
MSFT   376.87 (-0.52%)
META   324.26 (-2.39%)
GOOGL   131.87 (-2.31%)
AMZN   145.26 (-0.72%)
TSLA   241.21 (-1.20%)
NVDA   467.06 (-2.98%)
NIO   7.20 (+0.28%)
BABA   74.28 (-0.52%)
AMD   120.23 (-2.92%)
T   16.46 (+0.98%)
F   10.29 (-2.83%)
MU   75.73 (-1.25%)
CGC   0.55 (-1.34%)
GE   120.59 (+1.46%)
DIS   92.80 (+0.32%)
AMC   6.87 (-4.18%)
PFE   30.42 (+1.13%)
PYPL   57.38 (-1.02%)
XOM   102.54 (+0.20%)
S&P 500   4,543.60 (-0.15%)
DOW   35,683.43 (+0.71%)
QQQ   386.91 (-0.74%)
AAPL   188.57 (-0.42%)
MSFT   376.87 (-0.52%)
META   324.26 (-2.39%)
GOOGL   131.87 (-2.31%)
AMZN   145.26 (-0.72%)
TSLA   241.21 (-1.20%)
NVDA   467.06 (-2.98%)
NIO   7.20 (+0.28%)
BABA   74.28 (-0.52%)
AMD   120.23 (-2.92%)
T   16.46 (+0.98%)
F   10.29 (-2.83%)
MU   75.73 (-1.25%)
CGC   0.55 (-1.34%)
GE   120.59 (+1.46%)
DIS   92.80 (+0.32%)
AMC   6.87 (-4.18%)
PFE   30.42 (+1.13%)
PYPL   57.38 (-1.02%)
XOM   102.54 (+0.20%)
S&P 500   4,543.60 (-0.15%)
DOW   35,683.43 (+0.71%)
QQQ   386.91 (-0.74%)
AAPL   188.57 (-0.42%)
MSFT   376.87 (-0.52%)
META   324.26 (-2.39%)
GOOGL   131.87 (-2.31%)
AMZN   145.26 (-0.72%)
TSLA   241.21 (-1.20%)
NVDA   467.06 (-2.98%)
NIO   7.20 (+0.28%)
BABA   74.28 (-0.52%)
AMD   120.23 (-2.92%)
T   16.46 (+0.98%)
F   10.29 (-2.83%)
MU   75.73 (-1.25%)
CGC   0.55 (-1.34%)
GE   120.59 (+1.46%)
DIS   92.80 (+0.32%)
AMC   6.87 (-4.18%)
PFE   30.42 (+1.13%)
PYPL   57.38 (-1.02%)
XOM   102.54 (+0.20%)
S&P 500   4,543.60 (-0.15%)
DOW   35,683.43 (+0.71%)
QQQ   386.91 (-0.74%)
AAPL   188.57 (-0.42%)
MSFT   376.87 (-0.52%)
META   324.26 (-2.39%)
GOOGL   131.87 (-2.31%)
AMZN   145.26 (-0.72%)
TSLA   241.21 (-1.20%)
NVDA   467.06 (-2.98%)
NIO   7.20 (+0.28%)
BABA   74.28 (-0.52%)
AMD   120.23 (-2.92%)
T   16.46 (+0.98%)
F   10.29 (-2.83%)
MU   75.73 (-1.25%)
CGC   0.55 (-1.34%)
GE   120.59 (+1.46%)
DIS   92.80 (+0.32%)
AMC   6.87 (-4.18%)
PFE   30.42 (+1.13%)
PYPL   57.38 (-1.02%)
XOM   102.54 (+0.20%)

SkinBioTherapeutics Share Price, News & Analysis (LON:SBTX)

GBX 18.75
+0.13 (+0.67%)
(As of 05:07 PM ET)
Compare
Today's Range
18.50
▼
19.50
50-Day Range
18.53
▼
29
52-Week Range
11
▼
29.50
Volume
468,213 shs
Average Volume
416,040 shs
Market Capitalization
£35.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlines

SBTX stock logo

About SkinBioTherapeutics Stock (LON:SBTX)

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health. It develops SkinBiotix technology that can enhance the formation of multi-protein complexes and prevent passage toxins, molecules, and ions, as well as pathogens; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has a collaboration agreement with Croda Plc; and the University of Manchester to develop bacterial lysates in the prevention of periodontal gun disease. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

SBTX Stock Price History

SBTX Stock News Headlines

November 17, 2023 | uk.investing.com
SkinBioTherapeutics bags £3m at a modest discount
November 16, 2023 | marketwatch.com
SkinBioTherapeutics to Raise at Least $3.7 Mln
November 30, 2023 | Edge On The Street (Ad)
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
September 14, 2023 | uk.investing.com
Fiverr International Ltd DRC (F2VR34)
September 2, 2023 | uk.investing.com
Societatea de Producere a Energiei Electrice in Hidrocentrale Hidroelectrica SA (ROH2O)
July 11, 2023 | finance.yahoo.com
SBTX.L - SkinBioTherapeutics Plc
June 21, 2023 | marketwatch.com
SkinBioTherapeutics Gets Approval for Supplement Launch in Italy
March 30, 2023 | finance.yahoo.com
SkinBioTherapeutics Reports First Half 2023 Earnings
November 30, 2023 | Tomorrow Investor (Ad)
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
March 28, 2023 | marketwatch.com
SkinBioTherapeutics Shares Fall on Widened 1H Pretax Loss From Higher Costs
March 22, 2023 | finance.yahoo.com
Is SkinBioTherapeutics (LON:SBTX) In A Good Position To Invest In Growth?
December 21, 2022 | marketwatch.com
SkinBioTherapeutics Raises GBP2.6 Mln in Placing, Retail Offer
December 15, 2022 | marketwatch.com
SkinBioTherapeutics to Raise a Minimum of GBP2.5 Mln
October 14, 2022 | finance.yahoo.com
After losing 68% in the past year, SkinBioTherapeutics Plc (LON:SBTX) institutional owners must be relieved by the recent gain
August 31, 2022 | lse.co.uk
SkinBioTherapeutics shares fall as probiotic AxisBiotix-PS sales drop
August 31, 2022 | marketwatch.com
SkinBioTherapeutics Shares Fall After Worse-Than-Expected Supplement Sales
June 15, 2022 | proactiveinvestors.com
SkinBioTherapeutics puzzled by share price, says feedback positive for psoriasis treatment
June 13, 2022 | marketwatch.com
SkinBioTherapeutics Knows No Reason For Share Price Fall
May 20, 2022 | news.yahoo.com
What It's Like Inside a Burning Drift Car
May 20, 2022 | news.yahoo.com
Report raises concerns over lay-offs, cash flow at Cottage clinic; records issues resolved
May 18, 2022 | finance.yahoo.com
We're Keeping An Eye On SkinBioTherapeutics' (LON:SBTX) Cash Burn Rate
March 29, 2022 | lse.co.uk
SkinBioTherapeutics proposes Manprit Singh Randhawa as new CFO
March 29, 2022 | marketwatch.com
SkinBioTherapeutics Shares Drop 30% After Widened 1H Pretax Loss
February 17, 2022 | finance.yahoo.com
What Kind Of Shareholders Hold The Majority In SkinBioTherapeutics Plc's (LON:SBTX) Shares?
January 19, 2022 | marketwatch.com
SkinBioTherapeutics CFO to Step Down
January 18, 2022 | proactiveinvestors.com
SkinBioTherapeutics seeks full-time finance chief and NED to guide social media strategy
December 24, 2021 | markets.businessinsider.com
SkinBioTherapeutics : Result of AGM
See More Headlines
Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SkinBioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/03/2020
Today
11/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:SBTX
CUSIP
N/A
CIK
N/A
Web
www.skinbiotherapeutics.com
Phone
+44-161-4682760
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-3,000,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-111.74%
Return on Assets
-60.12%

Debt

Debt-to-Equity Ratio
9.03
Current Ratio
1.77
Quick Ratio
10.01

Sales & Book Value

Annual Sales
£21,949.00
Price / Sales
1,626.16
Cash Flow
GBX 2.08 per share
Price / Cash Flow
9.00
Book Value
GBX 1 per share
Price / Book
18.75

Miscellaneous

Outstanding Shares
190,360,000
Free Float
N/A
Market Cap
£35.69 million
Optionable
Not Optionable
Beta
2.10
The 10 Best AI Stocks to Own in 2024 Cover
The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Stuart John Ashman (Age 56)
    CEO & Executive Director
    Comp: $325.85k
  • Mr. Manprit Singh Randhawa (Age 39)
    CFO, Secretary & Director
    Comp: $177.98k
  • Dr. Catherine O'Neill
    Chief Scientific Officer & Member of Scientific Advisory Board
  • Laura Bey
    Head of Formulations
  • Ms. Melissa Greenwell
    Group Financial Controller

Key Competitors

View All Competitors

Insiders















SBTX Stock Analysis - Frequently Asked Questions

How have SBTX shares performed in 2023?

SkinBioTherapeutics' stock was trading at GBX 15.50 at the start of the year. Since then, SBTX shares have increased by 19.4% and is now trading at GBX 18.50.
View the best growth stocks for 2023 here.

How were SkinBioTherapeutics' earnings last quarter?

SkinBioTherapeutics Plc (LON:SBTX) posted its earnings results on Tuesday, March, 3rd. The company reported ($0.64) earnings per share (EPS) for the quarter.

What other stocks do shareholders of SkinBioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SkinBioTherapeutics investors own include Avacta Group (AVCT), Inspired (INSE), OptiBiotix Health (OPTI), Lb-shell (LBP), Anglo African Oil & Gas (AAOG), Big Sofa Technologies Group (BST), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES) and Shield Therapeutics (STX).

How do I buy shares of SkinBioTherapeutics?

Shares of SBTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:SBTX) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -